interim analysis

Genocea Reports Third Quarter 2015 Financial Results
www.businesswire.com

On October 7, 2015, Genocea reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

3
Like
Save
Today's Watch List: General Motors Company (NYSE:GM), Genocea Biosciences, Inc …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save
Moving Stocks: Intermolecular, Inc. (NASDAQ:IMI), Emerson Electric Co. (NYSE …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

9
Like
Save
Top Stories: Nivalis Therapeutics, Inc. (NASDAQ:NVLS), Itau Unibanco Holding …
www.stocktranscript.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save
Biotech Stocks With Optimistic Trend – Genocea Biosciences Inc (NASDAQ:GNCA …
www.wsobserver.com

The company, on October 7, 2015, declaredpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

4
Like
Save
Three Highly Unusual Volume Increases: Genocea Biosciences Inc (NASDAQ:GNCA …
www.wallstreetpoint.com

The Healthcare Company on October 7, 2015statedpositive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its …

8
Like
Save
Biotech Decliners: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ContraVir …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

5
Like
Save
Mid-Day ETF Update: ETFs, Stocks Struggle to Stay Higher as Oil Prices Fall on …
www.nasdaq.com

Genocea Biosciences (GNCA) rose 8.6% after reporting that interim analysis of Phase 2 data on its GEN-003 genital herpes vaccine demonstrated a statistically significant 58% reduction in the viral shedding rate, the primary endpoint of the study.

6
Like
Save